Pharmaron Beijing Co.,Ltd.(300759),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

300759 Pharmaron Beijing Co.,Ltd.

Closed 12-12 15:00:00

29.91

+0.86

+2.96%

High30.12	Low28.87	Vol34.84M
Open29.03	D1 Closing29.05	Amplitude4.30%
Mkt Cap53.18B	Tradable Cap42.44B	Total Shares1.78B
T/O1.04B	T/O Rate2.46%	Tradable Shares1.42B
P/B3.54	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"300759","market":"SZ","secType":"STK","nameCN":"Pharmaron Beijing Co.,Ltd.","latestPrice":29.91,"timestamp":1765523025000,"preClose":29.05,"halted":0,"volume":34843002,"delay":0,"changeRate":0.0296,"floatShares":1419000000,"shares":1778000000,"eps":0.8506,"marketStatus":"Closed","change":0.86,"latestTime":"12-12 15:00:00","open":29.03,"high":30.12,"low":28.87,"amount":1035000000,"amplitude":0.043,"askPrice":29.92,"askSize":267,"bidPrice":29.91,"bidSize":1154,"shortable":0,"etf":0,"ttmEps":0.8506,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":5,"adr":0,"adjPreClose":29.05,"symbolType":"stock","openAndCloseTimeList":[[1765503000000,1765510200000],[1765515600000,1765522800000]],"highLimit":31.96,"lowLimit":26.15,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1778195525,"isCdr":false,"pbRate":3.54,"roa":"--","peRate":35.163414,"roe":"8.05%","epsLYR":1.0133,"committee":0.168486,"marketValue":53186000000,"turnoverRate":0.0245,"status":0,"hkstockBrief":{"symbol":"03759","market":"HK","secType":"STK","nameCN":"PHARMARON","latestPrice":22.38,"timestamp":1765526889005,"preClose":21.3,"halted":0,"volume":4818150,"delay":0,"premium":"-32.17"},"floatMarketCap":42454000000},"requestUrl":"/m/hq/s/300759/tweets","defaultTab":"tweets","newsList":[{"id":"1150686106","title":"Hong Kong Stocks Movement | CRO Concept Stocks Plunge Collectively: GENSCRIPT BIO (01548) Drops Over 6%, PHARMARON (03759) Falls Over 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150686106","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150686106?lang=en_us&edition=fundamental","pubTime":"2025-11-21 14:52","pubTimestamp":1763707934,"startTime":"0","endTime":"0","summary":"CRO concept stocks experienced a collective decline in Hong Kong trading. As of press time, GENSCRIPT BIO (01548) dropped 6.05% to HKD 14.92, while PHARMARON (03759) fell 4.67% to HKD 20.8. VIVA...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300759","01548","HK0000306701.USD","BK1141","03347","BK0216","HK0000320264.USD","BK1576","03759","01873","HK0000320223.HKD","HK0000306685.HKD","BK1583"],"gpt_icon":0},{"id":"1165960695","title":"IPO Preview: \"Stockpiling Monkeys\" Drags Down Profits, Can Dingtai Pharma's \"Water Seller\" Story Hold Up?","url":"https://stock-news.laohu8.com/highlight/detail?id=1165960695","media":"Stock News","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165960695?lang=en_us&edition=fundamental","pubTime":"2025-11-20 13:49","pubTimestamp":1763617742,"startTime":"0","endTime":"0","summary":"Recently, according to disclosures by the Hong Kong Stock Exchange, Jiangsu Dingtai Pharmaceutical Research (Group) Co., Ltd. (referred to as Dingtai Pharma) submitted its listing application to the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK0216","03347","BK1576","300759","06127","BK1141"],"gpt_icon":0},{"id":"1198030445","title":"Norges Bank Increases Stake in Pharmaron with Purchase of 700,200 Shares at HK$23.81 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1198030445","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198030445?lang=en_us&edition=fundamental","pubTime":"2025-11-17 09:31","pubTimestamp":1763343062,"startTime":"0","endTime":"0","summary":"Latest data from the Hong Kong Stock Exchange reveals that on November 12, Norges Bank acquired an additional 700,200 shares of Pharmaron (03759) at HK$23.8072 per share, totaling approximately...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","BK1576","300759","03759","BK1141"],"gpt_icon":0},{"id":"1144353748","title":"Norges Bank Increases Stake in PHARMARON (03759) by 700,200 Shares at HK$23.81 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1144353748","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144353748?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:12","pubTimestamp":1763118763,"startTime":"0","endTime":"0","summary":"Latest data from the Hong Kong Stock Exchange shows that on November 12, Norges Bank purchased an additional 700,200 shares of PHARMARON (03759) at HK$23.8072 per share, totaling approximately...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300759","BK1141","03759","BK0216","BK1576"],"gpt_icon":0},{"id":"1175529012","title":"Norges Bank Increases Stake in PHARMARON (03759) by 518,200 Shares at HK$25.76 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1175529012","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175529012?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:06","pubTimestamp":1762340773,"startTime":"0","endTime":"0","summary":"Latest data from the Hong Kong Stock Exchange shows that on November 3, Norges Bank purchased an additional 518,200 shares of PHARMARON (03759) at HK$25.7617 per share, totaling approximately...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","300759","BK0216","BK1141","03759"],"gpt_icon":0},{"id":"1107280284","title":"PHARMARON (03759) Shareholder Lou Xiaoqiang Pledges 2.154 Million Company Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1107280284","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107280284?lang=en_us&edition=fundamental","pubTime":"2025-11-03 18:02","pubTimestamp":1762164155,"startTime":"0","endTime":"0","summary":"PHARMARON (03759) announced that it recently received notice from one of its actual controllers, Mr. Lou Xiaoqiang, and his concert party Ningbo Longtaikang Investment Management Co., Ltd. (referred...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759","BK1576","BK0216","300759","BK1141"],"gpt_icon":0},{"id":"1141467445","title":"Goldman Sachs Raises PHARMARON (03759) Target Price to HK$30, Q3 Revenue Slightly Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=1141467445","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141467445?lang=en_us&edition=fundamental","pubTime":"2025-11-03 16:52","pubTimestamp":1762159947,"startTime":"0","endTime":"0","summary":"Goldman Sachs issued a research report slightly lowering its net profit forecasts for PHARMARON (03759) by 0.1%, 0.1%, and 0.5% for 2025, 2026, and 2027, respectively. The firm maintains a \"Buy\"...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","03759","300759","BK0216","BK1141"],"gpt_icon":0},{"id":"1176841198","title":"CLSA Raises Pharmaron (03759) Target Price to HK$28.8, Maintains \"Outperform\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1176841198","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176841198?lang=en_us&edition=fundamental","pubTime":"2025-10-31 14:12","pubTimestamp":1761891131,"startTime":"0","endTime":"0","summary":"CLSA has released a research report stating that Pharmaron (03759, 300759.SZ) has revised its 2025 revenue growth guidance from 10%-15% year-on-year to 12%-16%, with adjusted non-IFRS net profit...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","03759","BK1141","BK0216","300759"],"gpt_icon":0},{"id":"1162716596","title":"UBS: Pharmaron (03759) Sees Accelerated New Order Growth in First Three Quarters, Raises Target Price to HK$32.9, Maintains \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1162716596","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162716596?lang=en_us&edition=fundamental","pubTime":"2025-10-30 17:11","pubTimestamp":1761815483,"startTime":"0","endTime":"0","summary":"UBS released a research report stating that Pharmaron (03759) reported a 13.4% year-on-year increase in Q3 revenue to RMB 3.65 billion, broadly in line with market and the bank's expectations of RMB...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","BK0216","300759","BK1576","03759"],"gpt_icon":0},{"id":"2579614149","title":"Pharmaron Acquires Majority Stake in Biortus Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2579614149","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579614149?lang=en_us&edition=fundamental","pubTime":"2025-10-29 00:00","pubTimestamp":1761667227,"startTime":"0","endTime":"0","summary":"Pharmaron Beijing Co., Limited has entered into a definitive agreement to acquire an 82.54% equity interest in Biortus Biosciences Co., Ltd. and its affiliates. The deal is expected to significantly enhance Pharmaron's technological platform and service capabilities in structural biology, complex protein production and analysis, and structure-based drug discovery. Biortus brings expertise in protein science, biological assaying, protein crystallization, and AI/ML-based computational platforms for protein complex design and structure analysis. The acquisition is set to strengthen Pharmaron's integrated, multi-modality services platform and expand its ability to serve global biopharmaceutical clients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or leg","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL4dNSTy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","300759"],"gpt_icon":0},{"id":"2579961421","title":"Pharmaron Acquires Biortus in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2579961421","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579961421?lang=en_us&edition=fundamental","pubTime":"2025-10-29 00:00","pubTimestamp":1761667200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUA7PBCCH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["300759","BK0216"],"gpt_icon":0},{"id":"1136499261","title":"PHARMARON (03759) Nominates Professor Zeng Jinfeng as Candidate for Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499261","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136499261?lang=en_us&edition=fundamental","pubTime":"2025-10-28 21:10","pubTimestamp":1761657016,"startTime":"0","endTime":"0","summary":"PHARMARON (03759) announced that Mr. Zeng Kunhong has voluntarily resigned from his positions as independent non-executive director of the third board of directors, as well as member of the audit...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","BK0216","300759","BK1576","03759"],"gpt_icon":0},{"id":"1191948248","title":"PHARMARON (03759) Reports Q1-Q3 Results: Net Profit Attributable to Shareholders Drops 19.76% YoY to RMB1.141 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1191948248","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191948248?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:52","pubTimestamp":1761655934,"startTime":"0","endTime":"0","summary":"PHARMARON (03759) announced its financial results for the first three quarters of 2025. The group recorded operating revenue of RMB10.086 billion, representing a year-on-year increase of 14.38%. Net...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","BK1141","300759","BK0216","03759"],"gpt_icon":0},{"id":"1120732392","title":"Hong Kong Stocks in Focus | PHARMARON (03759) Surges Over 5% After Signing Cooperation Framework Agreement with CityU","url":"https://stock-news.laohu8.com/highlight/detail?id=1120732392","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120732392?lang=en_us&edition=fundamental","pubTime":"2025-10-24 09:58","pubTimestamp":1761271092,"startTime":"0","endTime":"0","summary":"PHARMARON (03759) has experienced a rise of over 5%, currently up 5.43% at HKD 25.26, with a trading volume of HKD 45.11 million. As reported, on October 23, PHARMARON announced that it signed a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300759","BK1576","BK1141","BK0216","03759"],"gpt_icon":0},{"id":"1106916581","title":"PHARMARON (03759) Actual Controller Lou Xiaoqiang Pledges 3.45 Million Shares and Releases Pledge on 4.37 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1106916581","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106916581?lang=en_us&edition=fundamental","pubTime":"2025-10-09 21:32","pubTimestamp":1760016777,"startTime":"0","endTime":"0","summary":"PHARMARON (03759) announced that the company recently received notification from Lou Xiaoqiang, one of the company's actual controllers, regarding his pledge and release of pledge on some of the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","03759","BK1576","300759","BK1141"],"gpt_icon":0},{"id":"2567178914","title":"Pharmaron's Shaoxing Unit Passes US FDA On-Site Inspection","url":"https://stock-news.laohu8.com/highlight/detail?id=2567178914","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567178914?lang=en_us&edition=fundamental","pubTime":"2025-09-16 11:47","pubTimestamp":1757994430,"startTime":"0","endTime":"0","summary":"Pharmaron Beijing's  wholly owned unit, Pharmaron Shaoxing Pharmaceutical, has passed a pre-approval inspection by the US Food and Drug Administration, confirming compliance with current good manufacturing practices, a Monday Hong Kong bourse filing said.The inspection, conducted between May 29 and June 4, covered multiple GMP systems, including quality, production, equipment, packaging, and laboratory controls.Shares of the firm were down over 1% in Tuesday morning trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1141","BK0216","300759","BK1576","03759"],"gpt_icon":0},{"id":"1187192403","title":"Pharmaron Beijing Co.,Ltd. (300759.SZ) Subsidiary Pharmaron Shaoxing Passes US FDA On-Site Inspection","url":"https://stock-news.laohu8.com/highlight/detail?id=1187192403","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187192403?lang=en_us&edition=fundamental","pubTime":"2025-09-15 18:40","pubTimestamp":1757932818,"startTime":"0","endTime":"0","summary":"Pharmaron Beijing Co.,Ltd. (300759.SZ) announced that its wholly-owned subsidiary Pharmaron (Shaoxing) Pharmaceutical Co., Ltd. (\"Pharmaron Shaoxing\") underwent a current Good Manufacturing Practice...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","BK0216","03759","300759","BK1141"],"gpt_icon":0},{"id":"1157537488","title":"Hong Kong Stock Movement | CRO Concept Stocks Rise in Morning Trading, PHARMARON (03759) Gains Over 8% as Innovative Drug Clinical Trial Review and Approval Process Accelerates Again","url":"https://stock-news.laohu8.com/highlight/detail?id=1157537488","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157537488?lang=en_us&edition=fundamental","pubTime":"2025-09-15 11:10","pubTimestamp":1757905827,"startTime":"0","endTime":"0","summary":"CRO concept stocks surged in morning trading. As of press time, PHARMARON (03759) rose 8.11% to HK$25.58; Joinn Laboratories (06127) gained 6.27% to HK$24.76; WuXi Biologics (02269) climbed 4.88% to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300759","06978","BK1574","03759","BK1576","BK1161","159992","BK1141","BK0216"],"gpt_icon":0},{"id":"1196353644","title":"PHARMARON (03759): Xinzhong Kangcheng's Share Reduction Plan Completed with Total Disposal of 26.67 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1196353644","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196353644?lang=en_us&edition=fundamental","pubTime":"2025-09-04 18:58","pubTimestamp":1756983507,"startTime":"0","endTime":"0","summary":"PHARMARON (03759) announced that the company recently received a notification letter from Xinzhong Kangcheng and its acting-in-concert party Shenzhen Xinzhong Longcheng Investment Partnership...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","03759","300759","BK0216","BK1141"],"gpt_icon":0},{"id":"1167420432","title":"PHARMARON (03759) Reports Interim Results with Shareholders' Profit of RMB 701 Million, Down 37% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1167420432","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167420432?lang=en_us&edition=fundamental","pubTime":"2025-08-21 20:38","pubTimestamp":1755779930,"startTime":"0","endTime":"0","summary":"PHARMARON (03759) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 6.441 billion, representing a year-on-year increase of 14.93%. Shareholders' profit...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300759","BK1141","BK0216","BK1576","03759"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2019-01-28","address":"北京市大兴区北京经济技术开发区泰河路6号1幢八层","stockEarnings":[{"period":"1week","weight":0.024},{"period":"1month","weight":-0.0317},{"period":"3month","weight":-0.1138},{"period":"6month","weight":0.214},{"period":"1year","weight":0.0264},{"period":"ytd","weight":0.1734}],"companyName":"康龙化成(北京)新药技术股份有限公司","boardCode":"AI0073","perCapita":"--","boardName":"研究和试验发展","registeredCapital":"177819万元","compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"survey":"　　康龙化成(北京)新药技术股份有限公司的主营业务是提供从药物发现到药物开发的全流程一体化药物研究、开发及生产服务。公司的主要产品是实验室服务、CMC（小分子CDMO）服务、临床研究服务、大分子和细胞与基因治疗服务。2025年，公司获得了标普全球SPGlobal颁发的“行业推进者”（IndustryMover）称号。","serverTime":1765716714418,"listedPrice":7.66,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharmaron Beijing Co.,Ltd.(300759),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharmaron Beijing Co.,Ltd.(300759) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharmaron Beijing Co.,Ltd.,300759,Pharmaron Beijing Co.,Ltd.股票,Pharmaron Beijing Co.,Ltd.股票老虎,Pharmaron Beijing Co.,Ltd.股票老虎国际,Pharmaron Beijing Co.,Ltd.行情,Pharmaron Beijing Co.,Ltd.股票行情,Pharmaron Beijing Co.,Ltd.股价,Pharmaron Beijing Co.,Ltd.股市,Pharmaron Beijing Co.,Ltd.股票价格,Pharmaron Beijing Co.,Ltd.股票交易,Pharmaron Beijing Co.,Ltd.股票购买,Pharmaron Beijing Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharmaron Beijing Co.,Ltd.(300759),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharmaron Beijing Co.,Ltd.(300759) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction